 Since Mirum Pharmaceuticals Livmarli was approved for the treatment of cholestatic pruritus in patients with Alagille syndrome, its stock has fallen some 25. Although the only approved therapy for ALGS, maralixibat faces competition via Albireos Bylvay, which has a first-mover advantage in at least one other bile acid indication. 